glp-1 receptor agonist blood pressure reduction Frontiers The benefits of GLP1 receptors

In clinical trials of Liraglutide (1.8 mg) and Albiglutide (50 mg), liraglutide was superior for reducing HbA1c, but was more likely to lose weight in patients

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

But the triple mechanism intensifies some of these effects compared to what semaglutide and tirzepatide side effects look like individually

Recent Phase 3 data showed average weight reduction exceeding 28% in some participant groups after extended treatment periods

Nauck MA, Quast DR, Wefers J, Meier JJ

Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol